India pharmaceutical regulatory reforms

In mid‑July 2026, the Indian Pharmacist Association called for an independent inquiry into the Delhi Pharmacy Council, citing administrative lapses, prolonged graduate registration delays and possible financial misconduct after the council’s vice‑president resigned. The same period saw the Indian Pharmacopoeia Commission sign a memorandum of understanding with the Uttar Pradesh Promote Pharma Council to boost quality standards, regulatory compliance and post‑market surveillance across the pharmacy and medical‑device sectors.

By the end of July, the focus expanded from domestic oversight to international collaboration. At the Global Drug Regulatory Conclave in New Delhi, the Union Commerce Minister announced a push for tighter cooperation with drug regulators worldwide, aiming to accelerate access to high‑quality, affordable medicines and cement India’s role as a pharmaceutical innovation hub. Simultaneously, India’s ambassador to Panama reported negotiations to open the Panamanian market to Indian drug manufacturers, positioning Panama as a gateway to broader Latin American markets. Together, these steps illustrate a trajectory from addressing internal regulatory shortcomings to pursuing global partnerships that enhance the reach and credibility of India’s pharmaceutical industry.